Mrs Felicia Helene Mullane, | |
13776 Centerline Road, South Wales, NY 14139-9790 | |
(716) 655-6131 | |
(716) 655-6131 |
Full Name | Mrs Felicia Helene Mullane |
---|---|
Gender | Female |
Speciality | Physical Therapist |
Location | 13776 Centerline Road, South Wales, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1801016142 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | 0150731 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Felicia Helene Mullane, 13776 Centerline Road, South Wales, NY 14139-9790 Ph: (716) 655-6131 | Mrs Felicia Helene Mullane, 13776 Centerline Road, South Wales, NY 14139-9790 Ph: (716) 655-6131 |
News Archive
In a new JAMA editorial, a Boston University School of Public Health (BUSPH) researcher and a health research journalist outline common ways that media, governments, and industry and academic public relations press releases have incompletely and misleadingly reported coronavirus research, and how they can do better.
This coverage decision ensures that an estimated 30 percent of the 42 million people who participate in Medicare will be able to undertake physician-supervised weight-loss programs.
Illumina, Inc. today announced the next product in its TruSight line of content sets, TruSight Tumor, for NGS-based somatic variant detection in solid tumors.
Children in classrooms with inadequate material resources and children whose teachers feel they are not respected by colleagues exhibit more mental health problems than students in classrooms without these issues, finds a new study in the March issue of the Journal of Health and Social Behavior.
The Baylor College of Medicine Human Genome Sequencing Center has standardized its target enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases.
› Verified 8 days ago